BackIsracann Biosciences Overview
Isracann Biosciences Inc.

Isracann Biosciences Return on Equity

Isracann Biosciences (IPOT.CN) has a ROE of -3542.57%, below the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

-3542.57%

Return on Equity

-3542.57%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Isracann Biosciences (IPOT.CN) FAQ

The latest ROE for IPOT.CN is -3542.57%. That is below the sector sector average of 11.3%. Investors often review this figure alongside Isracann Biosciences's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, IPOT.CN currently prints -3542.57% for ROE, while the sector average sits near 11.3%. That is roughly 31460.7% below the sector mean. Large gaps often invite a closer look at Isracann Biosciences's growth, margins, and balance sheet.

Return on Equity shows how effectively Isracann Biosciences converts resources into returns. At -3542.57%, IPOT.CN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IPOT.CN's ROE (-3542.57%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.